Cardiovascular disease (CVD) is the leading cause of death globally and even in developed nations poses a significant health, social and economic burden. More than 10% of the UK population (7.6 million) live with CVD, with an estimated prevalence that is double that of Alzheimer’s disease and cancer combined1.
CVD has been identified as a key target by the UK government, Public Health England, NHS England and NHS Improvement. In an effort to tackle CVD, https://www.longtermplan.nhs.uk/publication/nhs-long-term-plan/ the NHS Long Term Plan has created specific targets in reduction of mortality through CVD risk prevention, with guidance on the importance of collaborative action between stakeholders. COVID-19 has undoubtedly caused huge disruptions in healthcare delivery; however, the front against CVD remains united and lessons have been learnt through the management of this pandemic. With growing support from national organisations, there are reasons for optimism.
As we emerge from the pandemic there is the challenge of dealing with its wider impact on health but also an opportunity to embrace new ways of working2.
During this patient case-based webinar you will have the opportunity to explore the central aims of the NHS Long Term Plan to improve CVD prevention and management, with the goal of improving quality of care for patients at risk of CV events.
Based on literature, we now have a better understanding of the impact of atrial fibrillation on morbidity and mortality, relevant to CVD and renal disease. 3 As such, this webinar will look at the practical implementation of the guidelines in a holistic way implementing the Detect, Protect and Perfect national agenda on Stroke prevention in Atrial Fibrillation.
1. https://www.bhf.org.uk/what-we-do/our-research/heart-statistics Accessed May 2022
2. https://ukhsa.blog.gov.uk/2021/02/12/cardiovascular-disease-building-back-better/ Accessed May 2022
3. Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ 2016;354:i4482. https://doi.org/10.1136/bmj.i4482
Professor Ahmet Fuat Professor Ahmet Fuat was a GP in Darlington, County Durham for 37 years, where he was CVD and Research Leads for Darlington Primary Care Network and Darlington GP Federation. He joined Oberoi Consulting as Medical Director in September 2023, and is soon to start as an Honorary Consultant Lipidologist/GPSI within the diabetes and endocrinology team at County Durham and Darlington Foundation Trust.
He has been a GPSI Cardiology for over 25 years, having undertaken a Postgraduate Diploma in Cardiology at Bradford University, graduating with distinction. He went on to be a tutor on the course for many years, teaching on HF, HVD, AF and IHD. He started the first one stop diagnostic and integrated heart failure clinic in the UK in 2002, with local colleagues.
His PhD by research, in heart failure diagnosis and management, including work on natriuretic peptides, generated several publications that have informed guidelines and led to the award of an Honorary Professorial Chair at Durham University. He has contributed to various NICE and ESC CVD and HF guidelines, and RCGP CKD/AKI toolkit.
He has held and holds various roles in CVD and research, including the immediate past President of the Primary Care Cardiovascular Society (PCCS) which he was instrumental in reforming and current education and research lead, Lipid and Heart Failure primary care lead for North East and North Cumbria Academic Health Science Network. He sits on the NHSE CVD Prevention Clinical Leadership group and NHSE expert advisory group for Heart Failure and Heart Valve disease. He was a founder member of CaReMe UK representing the PCCS.
He has a passion for medical education and remains an active lecturer, tutor and researcher. He is on the editorial boards of the British Journal of Cardiology and Primary Care Cardiovascular Journals and a peer reviewer for most high impact Cardiovascular journals and research bodies. His work in community cardiology, has been recognised with Fellowships from the RCGP, RCP London and RCP Edinburgh and the PCCS.
He has led many quality improvement initiatives over the years in HF, AF, Lipids, hypertension, diabetes and CKD. His work on HF was included in their BHF blueprint for HF. Much of this work was carried out using Oberoi digital audit platforms, as has been replicated by colleagues across the UK, benefiting patients and practices positively.
He oversees the clinical aspects of Oberoi Disease management digital platform developments in HF, AF, CKD, Diabetes and Lipids, ensuring they reflect current National/International guidelines, and enable primary care to achieve QOF, DES/IIF and CVDPrevent audit targets. He mentors and trains the team of HF specialist nurses and clinical pharmacists employed by Oberoi Consulting.
This webinar will NOT be recorded due to the presentation being the Intellectual Property of the speakers.
The Zoom link to join the event will be emailed to the email address you booked with. This may be received into your spam/junk inboxes, please check.
If you cannot locate the Zoom link, please email webinar@mediconf.co.uk for assistance.
We no longer offer the option to dial in using your phone due to the excessive fees charged.
Find us on LINKEDIN
© Copyright 2007 - 2025 MediConf ©, Inc. All Rights Reserved ©
Registered Office: MediConf Uk c/o LCW Consulting, SWP, Suffolk House, George Street, Croydon, Surrey, CR0 0YN
Registered in England No. 09705397. Company registered in England and Wales. VAT Registration Number: 219014242
Telephone: 01444 414 264
Website design & development by Dual Media Ltd
This site is intended for use by UK healthcare professionals.
Please select the appropriate option below.